Jansen RL - Search Results

1

Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.

Kerbusch T, de Kraker J, Keizer HJ, van Putten JW, Groen HJ, Jansen RL, Schellens JH, Beijnen JH. Kerbusch T, et al. Among authors: jansen rl. Clin Pharmacokinet. 2001 Jan;40(1):41-62. doi: 10.2165/00003088-200140010-00004. Clin Pharmacokinet. 2001. PMID: 11236809 Review.

2

Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin.

Kerbusch T, Jansen RL, Mathôt RA, Huitema AD, Jansen M, van Rijswijk RE, Beijnen JH. Kerbusch T, et al. Among authors: jansen m, jansen rl. Clin Pharmacol Ther. 2001 Aug;70(2):132-41. doi: 10.1067/mcp.2001.117283. Clin Pharmacol Ther. 2001. PMID: 11503007 Clinical Trial.

3

Phase II study on cisplatin and ifosfamide in recurrent high grade gliomas.

van den Bent MJ, Schellens JH, Vecht CJ, Sillevis Smit PA, Loosveld OJ, Ma J, Tijssen CC, Jansen RL, Kros JM, Verweij J. van den Bent MJ, et al. Among authors: jansen rl. Eur J Cancer. 1998 Sep;34(10):1570-4. doi: 10.1016/s0959-8049(98)00138-5. Eur J Cancer. 1998. PMID: 9893630 Clinical Trial.

4

Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel.

Bosch TM, Huitema AD, Doodeman VD, Jansen R, Witteveen E, Smit WM, Jansen RL, van Herpen CM, Soesan M, Beijnen JH, Schellens JH. Bosch TM, et al. Among authors: jansen rl, jansen r. Clin Cancer Res. 2006 Oct 1;12(19):5786-93. doi: 10.1158/1078-0432.CCR-05-2649. Clin Cancer Res. 2006. PMID: 17020985

5

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.

Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, Creemers GJ, Baars A, Dezentjé VO, Imholz ALT, Jeurissen FJF, Portielje JEA, Jansen RLH, Hamberg P, Ten Tije AJ, Droogendijk HJ, Koopman M, Nieboer P, van de Poel MHW, Mandigers CMPW, Rosing H, Beijnen JH, Werkhoven EV, van Kuilenburg ABP, van Schaik RHN, Mathijssen RHJ, Swen JJ, Gelderblom H, Cats A, Guchelaar HJ, Schellens JHM. Henricks LM, et al. Lancet Oncol. 2018 Nov;19(11):1459-1467. doi: 10.1016/S1470-2045(18)30686-7. Epub 2018 Oct 19. Lancet Oncol. 2018. PMID: 30348537

6

A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy.

Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, Creemers GJ, Baars A, Dezentjé VO, Imholz ALT, Jeurissen FJF, Portielje JEA, Jansen RLH, Hamberg P, Ten Tije AJ, Droogendijk HJ, Koopman M, Nieboer P, van de Poel MHW, Mandigers CMPW, Rosing H, Beijnen JH, van Werkhoven E, van Kuilenburg ABP, van Schaik RHN, Mathijssen RHJ, Swen JJ, Gelderblom H, Cats A, Guchelaar HJ, Schellens JHM. Henricks LM, et al. Eur J Cancer. 2019 Jan;107:60-67. doi: 10.1016/j.ejca.2018.11.010. Epub 2018 Dec 11. Eur J Cancer. 2019. PMID: 30544060

7

High-dose chemotherapy with autologous bone marrow support as consolidation after standard-dose adjuvant therapy in primary breast cancer patients with seven or more involved axillary lymph nodes.

Lalisang RI, Hupperets PS, ten Haaft MA, Jansen RL, Schouten HC. Lalisang RI, et al. Among authors: jansen rl. Bone Marrow Transplant. 1998 Feb;21(3):243-7. doi: 10.1038/sj.bmt.1701071. Bone Marrow Transplant. 1998. PMID: 9489646 Clinical Trial.

8

Repetitive weekly cycles of 4-day continuous infusion of recombinant interleukin-2: a phase I study.

Punt KC, Jansen RL, De Mulder PH, Batchelor D, Galazka A, Bolhuis RL, Stoter G. Punt KC, et al. Among authors: jansen rl. J Immunother (1991). 1992 Nov;12(4):277-84. doi: 10.1097/00002371-199211000-00009. J Immunother (1991). 1992. PMID: 1477079 Clinical Trial.

9

Cyclophosphamide, hexamethylmelamine, adriamycin and cisplatin combination chemotherapy in mixed mesodermal sarcoma of the female genital tract.

Jansen RL, van der Burg ME, Verweij J, Stoter G. Jansen RL, et al. Eur J Cancer Clin Oncol. 1987 Aug;23(8):1131-3. doi: 10.1016/0277-5379(87)90145-3. Eur J Cancer Clin Oncol. 1987. PMID: 3115787

10

Non-myeloablative allogeneic stem cell transplantation in patients with solid tumours and patients with a haematological malignancy.

Huugen D, Bos GM, Jansen M, Lalisang R, Jansen R, Wagstaff J, Schouten HC. Huugen D, et al. Neth J Med. 2002 May;60(4):170-3. Neth J Med. 2002. PMID: 12164395 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

67 results

Search Page